{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [3, 5], "question": "How did the adjusted EBITDA change from 2022 to 2023 for both the Degree Program Segment and the Alternative Credential Segment?", "prediction": "The adjusted EBITDA for both segments changed by $33.972 million (18.8%) for the Degree Program Segment and $11.743 million (21.1%) for the Alternative Credential Segment from 2022 to 2023.", "ground_truth": "The adjusted EBITDA for the Degree Program Segment increased by $34 million from $180.7 million in 2022 to $214.7 million in 2023, while the Alternative Credential Segment's negative adjusted EBITDA improved by $11.7 million from -$55.6 million in 2022 to -$43.9 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [1, 4], "question": "How did the level of impairment charges for goodwill change in the Degree Program Segment and Alternative Credential Segment from 2022 to 2023?", "prediction": "- **Degree Program Segment**:\n  - 2022: No impairment charges.\n  - 2023: No impairment charges.\n  - Change: No change; No impairment charges in both years.\n\n- **Alternative Credential Segment**:\n  - 2022: $79.0 million in impairment charges.\n  - 2023: $62.8 million in impairment charges.\n  - Change: Decrease by $16.2 million.", "ground_truth": "In the Degree Program Segment, there were no impairment charges for goodwill in either 2022 or 2023, whereas in the Alternative Credential Segment, goodwill impairment charges increased from $78.991 million in 2022 to $79.471 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [0, 3], "question": "How did Full Course Equivalent (FCE) enrollments change in both the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023?", "prediction": "- Degree Program Segment: FCE enrollments decreased by 39,061, or 16.7%.\n- Alternative Credential Segment: FCE enrollments decreased by 6%, but the exact number is not provided.", "ground_truth": "FCE enrollments decreased by 16.7% in the Degree Program Segment from 233,635 in 2022 to 194,574 in 2023, while they increased by 4.5% in the Alternative Credential Segment from 93,471 in 2022 to 97,647 in 2023."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 2], "question": "What were the main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021?", "prediction": "The main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021, were:\n\n1. Divestitures: Totaling $33.5 million negative impact.\n2. Inflationary cost pressures.\n3. Lower sales volumes in the dental market.\n4. Negative impact of foreign exchange: $24.1 million.", "ground_truth": "The decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 was primarily due to divestitures, lower sales volumes in the dental market, and inflationary cost pressures, as indicated by the financial data provided."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [2, 5], "question": "How did the impairment charges on property and equipment and the amortization expense related to intangible assets change from 2021 to 2022?", "prediction": "- **Impairment Charges (2021 to 2022)**:\n  - 2021: $788\n  - 2022: $18\n  - Change: Decreased by $770\n\n- **Amortization Expense (2021 to 2022)**:\n  - Not directly provided in the chunks, but total depreciation (including P&E) for 2021 was $24,242. Assuming intangible amortization is the difference between total depreciation and P&E depreciation:\n  - 2021: $24,242 - $21,096 = $3,146 (approx.)\n  - 2022: Not directly provided, but total depreciation for 2022 was $21,096 (assuming no change in allocation between P&E and intangibles).\n  - Change: Decreased, but difficult to quantify without 2022's intangible amortization figure.", "ground_truth": "The impairment charges decreased from $788,000 in 2021 to $18,000 in 2022, while amortization expense increased from $10,469,000 in 2021 to $15,480,000 in 2022."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 1], "question": "How did the operating income for Healthcare Solutions and Industrial Solutions segments change from 2021 to 2022?", "prediction": "Healthcare Solutions: Decreased by $19.6 million (from $69.4 million to $49.8 million).\nIndustrial Solutions: Decreased by $10.1 million (from $48.6 million to $38.5 million).", "ground_truth": "The operating income for Healthcare Solutions decreased by $43.5 million from $69.4 million in 2021 to $25.9 million in 2022, while for Industrial Solutions it decreased by $25.7 million from $48.6 million in 2021 to $22.8 million in 2022."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [2, 4], "question": "How much interest income did Block, Inc. earn from customer funds in 2023, and how did it compare to the previous years?", "prediction": "Chunk 1 provides information about changes in cash and cash equivalents, but it does not specify the amount of interest income earned from customer funds in 2023. Therefore, it is not possible to determine how it compares to previous years.", "ground_truth": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds, which was immaterial in both 2022 and 2021."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 2], "question": "How did the organizational structure change with respect to Block, Inc's management reporting in the fourth quarter of 2023 affect the allocation of BNPL platform financial results?", "prediction": "In the fourth quarter of 2023, Block, Inc. reorganized its business structure. The BNPL platform was previously allocated equally between Cash App and Square segments. Post-reorganization, the entire BNPL platform was moved into the Cash App segment, concentrating all its financial results there.", "ground_truth": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure, moving the business activities and management of its BNPL platform fully under the Cash App segment, thus ceasing the previous practice of allocating 50% of revenue and gross profit from the BNPL platform to both the Square and Cash App segments."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 4], "question": "How did the classification of consumer receivables and their allowance for credit losses change from January 31, 2022 to December 31, 2023?", "prediction": "From January 31, 2022 to December 31, 2023, the classification and allowance for credit losses on consumer receivables changed as follows:\n- **Non-delinquent loans**: Increased by $430,658,000 (26.2%).\n- **1 - 60 days past due**: Increased by $157,582,000 (53.3%), including an increase in cash in transit of $140.5 million.\n- **61 - 90 days past due**: Increased by $6,186,000 (30.0%).\n- **90+ days past due**: Increased by $12,193,000 (19.6%).\n- **Classified consumer receivables**: Decreased by $0.1 billion to $0.0 billion.\n- **Allowance for credit losses**:\n  - Beginning balance: $151,290,000 (2022)\n  - Provision for credit losses: $261,296,000 (2023)\n  - Charge-offs and other adjustments: ($228,845,000)\n  - Net change: $15,105,000 (end of 2023: $185,275,000)", "ground_truth": "The consumer receivables classified as 'Pass' increased to $2.5 billion with $185.275 million in credit loss allowance by December 31, 2023, from the time of Afterpay's acquisition in January 2022 where the beginning allowance was $115.552 million."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [4, 5], "question": "What was the percentage change in the net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023?", "prediction": "The net property and equipment value of C.H. Robinson Worldwide, Inc. decreased by $14,714 (8.5%) from December 31, 2022, to December 31, 2023.", "ground_truth": "The net property and equipment values decreased by approximately 9.2% from $159,432,000 on December 31, 2022, to $144,718,000 on December 31, 2023."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [1, 3], "question": "What were the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements?", "prediction": "Based on the provided chunks, the primary factors affecting C.H. Robinson's financial performance in 2023 were:\n\n1. **Revenue Growth**: The company handled approximately 19 million shipments and worked with more than 90,000 customers in 2023, indicating an increase in business volume.\n2. **Goodwill Testing**: The company bypassed the initial qualitative assessment (Step Zero Analysis) and directly performed Step One Analysis, which indicated that the fair value of most reporting units significantly exceeded their carrying values, reducing the risk of goodwill impairment.\n3. **Strong Stock Performance**: The company's stock price performance outpaced the S&P 500 and the Nasdaq Transportation indices from December 31, 2018 to December 31, 2023.", "ground_truth": "C.H. Robinson's financial performance in 2023 was primarily affected by weak freight demand and excess carrier capacity leading to reduced net income and operating cash flow, alongside declines in transportation rates."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [3, 4], "question": "How did the revenue recognition policy related to in-transit shipments change from December 31, 2022, to December 31, 2023?", "prediction": "The amount of revenue recognized for contracts where the transit period was partially complete declined significantly at December 31, 2023 compared to December 31, 2022, driven by macroeconomic and industry factors impacting the cost of purchased transportation.", "ground_truth": "The revenue for contracts where the transit period was partially complete declined from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023, due to macroeconomic and industry factors impacting transportation costs."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 5], "question": "What was the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, and how does it compare to the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of the same date?", "prediction": "- Total stock-based compensation expense for 2023: $231,312,000\n- Unrecognized compensation cost as of Dec 31, 2023: $354,800,000\n- Comparison: Unrecognized cost is 57% higher than the 2023 expense.", "ground_truth": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million, while the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 4], "question": "How did the research and development expenses change from 2022 to 2023 compared to sales and marketing expenses, and what were the main reasons for these changes?", "prediction": "**Research and Development Expenses**:\n- Change (2023 vs 2022): Decreased by $29.0 million (29.0%)\n- Main reasons:\n  - Decrease in BLUE-C clinical trial costs (enrollment completed)\n  - Increase in MCED and MRD research activities\n\n**Sales and Marketing Expenses**:\n- Change (2023 vs 2022): Decreased by $48.5 million\n- Main reasons:\n  - Decrease in direct marketing costs, professional fees, and personnel expenses due to realignment of sales force and completion of Pfizer promotion agreement", "ground_truth": "Research and development expenses increased by $32.5 million due to higher personnel expenses and facility costs, while sales and marketing expenses decreased by $118.9 million primarily due to reduced marketing costs and a realignment of the sales force."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [1, 3], "question": "How did Exact Sciences Corporation’s cash and cash equivalents at the end of 2023 compare with their amount at the beginning of the year, and what was the cause of this change based on their cash flow activities?", "prediction": "At the end of 2023, Exact Sciences Corporation had $609,675 in cash and cash equivalents, compared to $242,790 at the beginning of the year. This increase of $366,885 was primarily driven by the following cash flow activities:\n\n1. **Operating Activities**: Net cash provided by operating activities was $156.1 million.\n2. **Financing Activities**: Net cash provided by financing activities was $159.8 million.\n3. **Investing Activities**: Net cash used in investing activities was ($1,082.1 million), which was mostly due to expenses related to acquisitions, investments in privately-held companies, and purchases of property, plant, and equipment. However, this was offset by proceeds from maturities and sales of such investments.\n\nThe change is largely due to the substantial net cash inflows from operating and financing activities, which exceeded the significant net cash outflows from investing activities.", "ground_truth": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million by the end of the year, driven by positive net cash provided by operating activities and an increase in net cash provided by financing activities, including proceeds from the issuance of convertible notes."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 1], "question": "How much did Esperion's net product sales increase from 2022 to 2023, and how much did their collaboration revenue increase within the same period?", "prediction": "Esperion's net product sales increased by $22.4 million from 2022 to 2023, and their collaboration revenue increased by $18.4 million within the same period.", "ground_truth": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, while their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [1, 4], "question": "How did Esperion Therapeutics, Inc.'s net loss change from 2022 to 2023 and what were the factors contributing to this change?", "prediction": "Esperion Therapeutics, Inc.'s net loss decreased from $233,659 in 2022 to $209,248 in 2023. This decrease was primarily driven by:\n- A $24,391 increase in total revenues (from $75,475 to $99,866), mainly due to higher product sales and collaboration revenue.\n- A $13,804 decrease in operating expenses, primarily attributed to a decrease in selling, general and administrative expenses offset by an increase in cost of goods sold and research and development expenses.\n- Other factors contributing to the decrease in net loss included a $2,639 decrease in interest expense and a $2,639 increase in other income, net.", "ground_truth": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, primarily due to increased net product sales and collaboration revenue, partially offset by increased selling, general, and administrative expenses."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 2], "question": "What changes occurred in the net product sales of NEXLETOL and NEXLIZET from 2022 to 2023, and how did the collaboration revenue compare during the same period?", "prediction": "- Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, a change of $22.4 million.\n- Collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023, a change of $18.4 million.", "ground_truth": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, while collaboration revenue also grew from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [2, 5], "question": "What was the percentage change in the Company's total revenue from the Property & Casualty insurance vertical from 2021 to 2023, compared to the Health insurance vertical for the same period?", "prediction": "The company's revenue from the Property & Casualty insurance vertical decreased by 26.8% from 2022 to 2023, while the Health insurance vertical decreased by 0.6% in the same period.", "ground_truth": "The Company's total revenue from Property & Casualty insurance vertical decreased by 60.7% from $417,715,000 in 2021 to $164,234,000 in 2023, while the Health insurance vertical saw a 5.6% increase from $176,459,000 in 2021 to $186,275,000 in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [0, 5], "question": "How did the revenue from Open Marketplace transactions compare to Private Marketplace transactions in the year ended December 31, 2023?", "prediction": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730 in transaction value, while Private Marketplace transactions generated $214,708.", "ground_truth": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730,000 in revenue, which was significantly higher than Private Marketplace transactions which generated $9,419,000."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [3, 4], "question": "How did the decrease in P&C insurance revenue contribute to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022?", "prediction": "The decrease in P&C insurance revenue of $70,923,000 (26.8% of total revenue) was the largest contributing factor to the overall decline in total revenue of $70,923,000 (15.4% of total revenue) for the year ended December 31, 2023 compared to 2022.", "ground_truth": "The P&C insurance revenue decreased by $60.1 million in 2023, primarily due to reduced customer acquisition spending by P&C carriers, contributing significantly to the overall decline in total revenue by $70.9 million compared to 2022."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [2, 4], "question": "What are the potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations?", "prediction": "1. **Data Exclusivity**: If the proposed reduction in data exclusivity from 8 to 6 years is adopted, it could shorten Mind Medicine's market exclusivity period, potentially allowing generic or biosimilar competitors to enter earlier, impacting revenue and profits.\n\n2. **Medical Device Regulations**:\n   - **CE Marking**:Products placed on the EU market must comply with revised MDR. If non-compliance occurs, CE Marks may be withdrawn, impact sales in Europe.\n   - **Post-Market Surveillance**: Continuously monitor and report product performance and safety, which could increase operational and regulatory burden.\n   - **Combined Products**: Combination medicinal products/devices may face additional regulatory hurdles and scientific opinions regarding medicinal product quality and safety.\n   - **Brexit**: CE Mark is no longer automatically recognized in GB, requiring dual marking (CE and UKCA) for products placed in both EU and GB markets, potentially impacting costs and sales.", "ground_truth": "Regulatory changes in the EU, such as the proposal to reduce data exclusivity from eight to six years and the MDR governing medical devices, could affect Mind Medicine's product development timelines and compliance requirements, impacting their ability to market products efficiently in the EU."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [3, 4], "question": "Between December 31, 2022, and December 31, 2023, how much of the equity securities registered under the shelf registration statement was issued by the company?", "prediction": "At December 31, 2022, $100.0 million was reserved for sales under the ATM. At December 31, 2023, $59.8 million remained available for issuance, with $40.2 million having been issued under the ATM.", "ground_truth": "Between December 31, 2022, and December 31, 2023, the company issued $0.2 million of equity securities, as the availability decreased from $100.0 million to $99.8 million."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [1, 3], "question": "What are some potential consequences mentioned in the financial statements if the company fails to comply with controlled substance laws and regulations when developing its product candidates?", "prediction": "- Significant fines, penalties, administrative sanctions, convictions or settlements\n- Criminal charges and penalties including imprisonment\n- Material adverse effects on business, reputation, and financial position\n- Difficulty in estimating investigation or defense costs\n- Illegal to aid or abet such activities or conspire to engage in them", "ground_truth": "Failure to comply with controlled substance laws and regulations may result in increased costs, enforcement actions, regulatory scrutiny, potential litigation, and criminal prosecution, which could delay or prevent product development and commercialization."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [0, 2], "question": "What percentage of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment, and what challenges does this concentration pose?", "prediction": "13% of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer (Customer A) within the Compute & Networking segment. The concentration poses risks of adverse effects on revenue if NVIDIA loses this customer or if the customer reduces its purchases.", "ground_truth": "Sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, posing challenges like potential revenue impact from losing or being unable to sell to such major customers due to trade restrictions."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 5], "question": "What was the change in NVIDIA's net income from January 29, 2023, to January 28, 2024, and how does this compare to the change in revenue for the same period?", "prediction": "**Change in Net Income**: $25,392 million (from $4,368 million to $29,760 million)\n**Change in Revenue**: $33,948 million (from $26,974 million to $60,922 million)\n**Comparison**: Net income increased by about 72% of the revenue increase.", "ground_truth": "NVIDIA's net income increased from $4.37 billion on January 29, 2023, to $29.76 billion on January 28, 2024, while revenue increased from $26.97 billion to $60.92 billion during the same period."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 2], "question": "What percentage of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, and how does this demonstrate a risk presented in the Risk Factors?", "prediction": "Customer A accounted for 13% of NVIDIA's total revenue in 2024, representing a significant portion of the Compute & Networking segment's revenue. This concentration of revenue from a single customer is indeed a risk factor highlighted in NVIDIA's financial statements, as it could potentially impact the company's financial performance if business from Customer A were to decline or be lost.", "ground_truth": "In fiscal year 2024, 13% of NVIDIA's revenue came from a single customer in the Compute & Networking segment, illustrating the risk of revenue concentration from limited partners and distributors, as mentioned in the Risk Factors."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [1, 3], "question": "How did Paratek's financial position affect their ability to utilize net operating loss carryforwards after the merger, and what was the impact on regulatory operations?", "prediction": "- **Impact on Utilization of NOLs:** Paratek's merger resulted in Sections 382 and 383 ownership change limitations, potentially impacting their ability to fully use NOLs and R&D credits to offset future taxable income. Management believes they might not recognize the benefits of $189.6M (federal) and $188.9M (state) in deferred tax assets due to NOLs' limited usability.\n- **Impact on Operating Results:** If Paratek cannot utilize a material portion of their NOLs and other tax benefits, this could have a material adverse effect on cash flow and results of operations.", "ground_truth": "Paratek's financial position was impacted by ownership changes from the merger that limited the use of net operating loss carryforwards, which could materially affect cash flow and operations as government regulations require cost compliance in various areas."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [3, 4], "question": "How did the full-year net product revenue change for Paratek Pharmaceuticals' NUZYRA from 2021 to 2022, and what was the impact on the company's net loss for the same period?", "prediction": "- Net product revenue increased from $106.084 million in 2021 to $136.820 million in 2022, a rise of $30.736 million.\n- Net loss went from $59.084 million in 2021 to $63.566 million in 2022, indicating a worsening by $4.482 million.", "ground_truth": "The net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, while the net loss increased from $59.1 million in 2021 to $63.6 million in 2022."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [0, 2], "question": "What are the factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements?", "prediction": "From the provided chunks, here are the key factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements:\n\n1. **Building and maintaining internal sales, distribution, and marketing capabilities**\n2. **Widespread acceptance by physicians, healthcare payors, patients, and the medical community**\n3. **Proper pricing, coverage, and adequate reimbursement**\n4. **Compliance with ongoing FDA labeling, packaging, storage, advertising, promotion, recordkeeping, safety, and other PMRs**\n5. **Managing costs and expenses commensurate with NUZYRA’s projected growth**", "ground_truth": "The success of NUZYRA's commercialization in the U.S. depends on securing starting materials, maintaining manufacturing arrangements, producing sufficient quantities, building sales and marketing capabilities, gaining product acceptance, obtaining sufficient reimbursement, and maintaining compliance with FDA requirements as mentioned in the financial statements."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 2], "question": "What were the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023?", "prediction": "- **Automotive Sales Revenue:**\n  - Increased deliveries (+17% YoY)\n  - Stricter average cost per unit due to sales mix\n  - Lower inbound freight and material costs\n  - Improved fixed cost absorption\n  - Stronger USD against foreign currencies\n  - IRA manufacturing credits\n\n- **Gross Margin (Total Automotive & Services & Other Segment):**\n  - Lower average selling price on vehicles\n  - Favorable change in average combined cost per unit\n  - IRA manufacturing credits", "ground_truth": "Automotive sales revenue increased by $11.30 billion due to a rise in Model 3 and Model Y deliveries, while the gross margin decreased from 28.5% to 19.4% due to lower average selling prices and increased costs."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [3, 5], "question": "How did Tesla's short-term investments and inventory change from December 31, 2022, to December 31, 2023?", "prediction": "Short-term investments decreased by $3,562M (from $16,253M to $12,691M), Inventory decreased by $4,670M (from $7,004M to $2,334M) from December 31, 2022, to December 31, 2023.", "ground_truth": "Tesla's short-term investments increased from $5,932 million in 2022 to $12,696 million in 2023, while inventory increased from $12,839 million in 2022 to $13,626 million in 2023."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 5], "question": "How do the commitments for capital expenditure and tax revenues in the state of New York compare to those in Shanghai, China for Tesla as of December 31, 2023?", "prediction": "**New York (Buffalo):**\n- $5.00 billion combined capital, operational expenses, costs of goods sold and other costs over 10 years.\n- Reduced to $5.00 billion through December 31, 2029.\n\n**Shanghai (Gigafactory):**\n- RMB 14.08 billion (approx. $2.13 billion) in capital expenditures by end of 2023, achieved.\n- RMB 2.23 billion ($338 million) annual tax revenues starting 2023.\n\n**Comparison:**\n- Total capex commitment in New York is higher, but spread over a longer period.\n- Tax revenues in Shanghai are annually committed, with a significant amount per year.", "ground_truth": "As of December 31, 2023, Tesla committed to $5 billion in combined expenditures and costs in New York state by the end of 2029, while in Shanghai, China, Tesla committed to RMB 14.08 billion in capital expenditures and RMB 2.23 billion in annual tax revenues by the end of 2023, both of which have been achieved."}
